Zenith Drugs

Quick check

The five things to look at first. Open one for more.

• DebtLook closerRated BB+ by CRISIL.
• ResultsProfit fallingIn the Mar 2026 quarter, sales rose 50% and profit fell 50% from a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersSteadyThe promoters (founders or parent) own 70% of the company, about the same as in Mar 2024.
• ValuationCheap vs its pastThe share trades at 6 times its yearly earnings (P/E), cheaper than 100% of the time in the last 3 years. Its usual P/E is about 11.

Zenith Drugs against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)6 against a typical 34.3: cheaper than most peers (1st = cheapest).9th of 220
• Sales growth+50% against a typical +15.6% from a year earlier.31st of 197
• Profit growth−50% against a typical +18.9% from a year earlier.133rd of 160
• Share price, 3 months−22.8% against a typical −0.5%.188th of 200

Exchange filings and their impact on the company.

• 13 Oct 2026Outcome of Board MeetingMedium impactPositivePrice −0.8% that day
  Board approves Rs 13.75 cr sale of idle Indore land and building to raise cash and strengthen balance sheet.

  Zenith Drugs board on October 13, 2026 approved sale of its 5-hectare land and building at Plot UD-7, Industrial Park, Mohana, Indore for Rs 13.75 crore to ACE Engineering & Chemicals Private Limited, a non-promoter buyer. The company said the property contributes 0% of turnover and is about 18.57% of net worth, with sale deed by October 20 and completion and payment by November 20, 2026. The cash inflow from this idle asset should help reduce its Rs 55 crore borrowings and interest burden with no impact on sales.

  Full analysisFiling
• 10 Oct 2026General UpdatesLow impactPositivePrice −1.5% on 12 Oct
  Wins 2-year Haryana government cough-syrup supply contract at Rs 11.15 per bottle, a small revenue add.

  Zenith Drugs received a Letter of Acceptance from Haryana Medical Services Corporation for supply of cough syrup (Ambroxol-Terbutaline-Guaiphenesin-Menthol 100ml) to Haryana government hospitals for two years under Tender No. 384. The accepted rate is Rs 11.15 per bottle inclusive of taxes, with no fixed quantity or total value disclosed. It is a small rate-contract win that should add modest revenue over the next 12 months with thin government-tender margins.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Neeraj Pandey

Chief Financial Officer

Sakshi Bhawsar

Company Secretary and Compliance Officer

Sandeep Bhardwaj

Managing Director, Executive Director

Ajay Singh Dassundi

Executive Director

Bhupesh Soni

Executive Director